Antibodies- New Delhi: In a study by researchers at the Indian Council for Medical Research (ICMR), 58.1% of people who received a single dose of the Kovidhield vaccine did not show neutralizing antibodies against the delta variant (B1 .617.2) in serum samples. At the same time, no neutralizing antibodies were found in 16.1% of samples from people who took two doses.
According to Dr. T. Jacob John, former head of the microbiology department at Christian Medical College, Vellore, “The presence and absence of antibodies are not the same thing. The level of neutralizing antibodies may be too low to be detected. ” But it can be present and protect the person from infection, from serious illness.
Inhibit entry of the CoV-2 virus into cells by titers of
neutralizing antibodies, which specifically target the Sars-CoV-2 virus and kill it or prevent it from entering human cells. These titres were lower against the delta variant than against the B1 variant. The first wave of infection has arrived in India due to the B1 variant. Compared with B1, neutralizing antibody titers against the delta variant were 78% lower in people taking one dose of the vaccine, 69% lower in those taking two doses. Other than that, those infected and taking a dose were 66% fewer. Along with this, those infected and given both injections were 38% fewer.
The study means that some may need an additional booster on top of Kovidshield in India’s vaccination campaign, while those with the infection may only need a single dose.
One dose may be sufficient for those infected
. According to Dr. John, “Assuming that the serum used for the study came from healthy individuals, the level of neutralizing antibodies would be higher in the elderly. Due to their weak immune response, this means that men over 65 (women produce higher levels of antibodies), diabetes, high blood pressure, people with heart, lung, kidney or disease. cancer must be treated to respond to the third dose. people who have been infected “
